Synopsis
Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products. 9/19/2025 Traditional Approval Granted (10/16/2026) Brukinsa (zanubrutinib) Formulation: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.
Read the full story at FDA: drugs ↗
